while National Health System (SNS) continues to recover from health crisis happened In recent years, due to the COVID-19 pandemic, all the actors that make up the sector have faced, in parallel, new agreements that have come to the fore in 2022, such as supply crisisThe high cost of energy and other related factors Production and late access to innovation,
Looking ahead to 2023, the healthcare industry has already turned its attention to the innovations that will evolve healthcare health Departmentprocessing of new guarantee law why Digitization of National Health System (SNS), For their part, the concerns that are being drawn such as the aforementioned supply crisis and requests for indexed prices continue at the start of the new season.
hence, Global Speaks to Key Representatives of the Healthcare Industry To find out what are their expectations, challenges and special needs for the new financial year.
The transformation of SNS and its adaptation to the ‘postcovid’ era Vanguard Health PERTE The main axis on which it rotates. Government launches this mechanism in 2021, inching closer to a global endowment €1.5 billionhas a deadline this 2023 to execute on the strategies and investments it considers.
Thus, 2023 is the key year for its full materialisation, which justifies the special look that the sector puts on it for the new year. “2023 should be the year in which we continue to move towards more modern, intelligent and digital SNS. To this end, we must strengthen public-private cooperation with strategic and essential sectors, and PERTE Salud de Vanguardia and NEXT Generation EU funds should optimize the opportunities offered by the Margarita Alfonso, Secretary General of the Spanish Federation of Health Technology Companies (FENIN),
From the Association of Biotechnology Companies (ACEBIO) They also emphasize the need to optimize this PERTE and, in particular, investment and execution time. “We celebrate the various calls and tools through which PRTE is being done. However, although it is designed with a business to collaboration, the specific tools have not been able to engage academia and industry in equal parts Of the 989 million euros programmed for biotechnology companies, about 2% has arrived”, Mann Ion Arosena, its General Manager, Now, from Asebio we enter 2023 with a positive mindset: “We are sure that this ratio will get better”, specifies Arocena.
law of guarantee
If there is one sector that is accustomed to being aware of the legislative sphere, it is the health and pharmaceutical sector. In this context, 2023 will not be an exception. There are several standards to meet in the new year as indicated by the health industry. Above all, because of its direct effect, New law on guarantees first draft expected imminently -Director General of Pharmacy of the Ministry, César Hernández, The final stretch of this 2022 was set as the date,
For example, in relation to this law, Spanish Association of Generic Medicine (AESEG) He hopes that its development can include pro-generic measures “that will help us get out of the impasse in which we have been for seven years. For example, with measures aimed at price discrimination between generic and brand medicine or preferential distribution conditions,” he explains. Angel Luis Rodríguez de la Cuerda, President of AESEG,
since agro IndustryAssure that we are “before the opportunity to reduce the vulnerability of the supply of medicines classified by the Spanish Medicines Agency (Aemps) as strategic, Adequately identify treatments that provide incremental innovation and improving access to innovation by patients”, thanks to the reform of the aforementioned legislation.
for his part, heAn Association for the Self-Care of Health (ANEFP) He also describes it as a “challenge” to participate in the exercise. In this sense its chairman Jaume Pey states that since cooperation and responsibility“We will work with the Health Administration to adapt the self-care sector to the new paradigms that current events are driving, to provide citizens with their health care and to continue to respond to the health system, contributing to its sustainability”.
hence, Director of the Spanish Association of Biosimilar Medicines ,Biosim), Encarna Cruzassures that “it can bring solutions to challenges related to pricing and financing decisions, reference price systems, reforms in drug procurement procedures and firm commitment to national policies to promote biosimilars”.
Similarly, the biosimilar sector expects “with great confidence” that, if the process is completed in the rest of the legislature, “The new text is fitted with the biosimilar concept in all classes that are lacking today”Cruz connects.
If there’s one problem that cuts across the entire healthcare industry in 2022 and it seems Supply crunch (lack of availability of raw materials) and unprecedented rise in cost of factors such as energy and transportation Which are important in the productive activity of the companies.
“We are concerned that, if urgent measures are not taken, the supply and electronic components crisis that our industry has faced in 2022, coupled with the unprecedented increase in production costs, extends to the whole of 2023 and compromises the viability of public contracts And, therefore, access to technology and health products”, says FENNIN Secretary General regarding the health technology sector.
The field of generic drugs is also cautious – “without causing social alarm,” the general directors of their employers specify regarding the issue. “There is no current risk of shortages, but in the medium term, there may be a risk of discontinuation of some products, as a result of increased direct and indirect manufacturing costs and less regulated prices”Rodriguez de la Cuerda explains.
The general director of Eseg recalls that “the increase in the prices of products is having an effect in other areas, but we must not forget that The price of drugs is regulated and fixed, Therefore, the employer is requested to take into account the increase in the cost of production due to increase in the prices of energy, raw materials etc. “And since there is no indexation of prices based on CPI, an increase in the price of these medicines by about 10% can be considered to guarantee the supply of these medicines,” he confirms.
This request coincides with a request raised by Fannin, who asked the administration to plan a staggered “to prevent the consequences of this crisis from spreading throughout the new year”Alfonselle points out, and who consider as a key measure that public contracts should enable indexing mechanisms that make them more flexible to rise or fall in prices taking into account the current state of production costs.
Strategic Planning for the Pharmaceutical Industry
At the national level, the priority of the innovative pharmaceutical industry goes through Strategic plan for the pharmaceutical industry in SpainThe foundation of which was laid just a few days back in a meeting organized by the top representatives of farmindustry and companies across the world with the President of the Government, pedro sanchezand ministers of health, Industry why science,
“This plan represents an excellent opportunity to create a strong industrial and innovation policy in the life sciences sector that turns our country into an attractive market for investments in this sector and includes one of the priorities of the Spanish Presidency in Europe support for the pharmaceutical industry.In the second semester of 2023, of the Council of the European Union, They are influenced by Farmindustria,
european pharmaceutical strategy
On the other hand, at the continental level, BioSim recalls that it is expected that by 2023.Amendment to the EU general law on medicinal products for human useWhich was expected for the last four months of 2022.
“It stems from regulatory updates European Pharmaceutical Strategy, and to improve patient access. Biosimilar medicines contribute greatly to this objective”, said the Director of BioSim.
The Anefp also focuses on other continental regulations in force in Spain: “Application of the Rational Medicines Regulation or the Health Products Regulation”, praises Pe.
And, continuing in a continental key, Fannin also expects Spain to finally implement one in 2023. less VAT Such a possibility is already allowed to member states for all sanitary products since the reform of the European VAT Directive carried out in May 2022.
Other issues in view of the sector
- Develop investment plans and area objectives for 2023-2025.
- Strengthen Spain’s leadership in preclinical research and strengthen translational and clinical research.
- Creation of the European Biosimilar Observatory.
- Implementation of profit-sharing programs with biosimilars.
- Establish measures aimed at price discrimination or preferential distribution conditions.
- Update minimum price range.
- Development of the strategic plan for the self-care sector in Spain 2023–24.
- Extension of self-regulation process Seal NEFP to new self-care segments.
- Renovation of Health Technology Park (Full execution of INVEAT scheme in 2023).
- Industrialization planning for the health technology sector.
- Acceleration of the Biotechnology sector pipeline (Made in Spain solution).
- Strengthen leadership in testing and innovation with greater access to funding.